Postmastectomy radiotherapy in male breast cancer –20 Years follow-up data

2011 ◽  
Vol 71 (08) ◽  
Author(s):  
H Eggemann ◽  
A Ignatov ◽  
R Stabenow ◽  
G von Minkwitz ◽  
FW Röhl ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Postmastectomy Radiotherapy

scholarly journals Evaluation of General, Pathological, and Radiological Features of Male Breast Cancer

2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Fariba Zarei ◽  
Fereshte Bagheri ◽  
Amin Dehdashtian ◽  
Majid Akrami
Keyword(s):  
Breast Cancer ◽  
Survival Time ◽  
Male Breast Cancer ◽  
Medical Records ◽  
Male Breast ◽  
Treatment Modalities ◽  
Time Interval ◽  
Number Of Patients ◽  
History Of

Background: Male breast cancer (MBC) is an infrequent disease and a scarcely researched topic. Since the incidence of male breast cancer is increasing and so far, management advices have been concluded from results of trials in female patients, there has been a growing interest in this field of research. Objectives: In this study, we aimed to evaluate the general, radiological and pathological features of MBC patients. Patients and Methods: We retrospectively reviewed the medical records of MBC patients who had been referred to breast clinic, Shahid Motahari in Shiraz, Iran, between 2005 and 2018. Data regarding general characteristics of patients such as demographic information, age, and also past history of any cancer, family history of breast cancer, mammogram and ultrasound findings, stage, size and location of tumor, histopathology of tumor, metastasis, treatment modalities and follow-up time were attained by reviewing medical records. Results: Fifty-one patients with MBC were included with the mean age of 58.4 years. Invasive ductal carcinoma was the most prevalent pathologic type. By use of the Kaplan Meier survival estimate, survival probability of patients for each time interval after diagnosis was calculated. There was a decline over time until about 85 months after diagnosis when it reached a plateau state above 50%. Age, human epidermal growth factor receptor 2 (HER2) and metastasis showed to lower the survival time by increasing the hazard ratio. Only 13 patients had mammography and 22 had an ultrasound, which are less than 50% of the total number of patients. Conclusions: This study showed that there is still unfulfilled need to evaluate MBC in order to find the best management guidelines such as screening in high risk populations, diagnosis, treatment, and follow-up. Risk factor evaluation, survival time, and diagnostic radiologic modalities have not been well assessed in MBC so far.

Metastatic male breast cancer (mMBC): Prognosis and survival of 35 patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e12001-e12001
Author(s):  
R. Foerster ◽  
F. G. Foerster ◽  
D. Baaske ◽  
B. Schubotz ◽  
V. Wulff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Systemic Therapy ◽  
Metastatic Breast ◽  
Male Breast ◽  
Tumor Characteristics ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Radio Therapy

e12001 Background: Only about 1% of breast cancers occur in men, respectively 400–500 new cases per year in Germany. Clinical studies on breast cancer in men are limited for case studies or retrospective analysis. In the recent years no studies have been published on the clinical course of mMBC. Therefore we here present a retrospective cohort study on this topic. Methods: Clinical and pathological tumor characteristics and the follow-up of male breast cancer patients with metastatic disease diagnosed in the region Chemnitz/Zwickau in the state of Saxony between 1995 and 2007 were documented and statistically evaluated. Results: 35 men (median age 64.7 years) were diagnosed with mMBC; 10 (28.6%) of them with primary metastasis. Median survival time: 37 months. 85.7% (n = 30) had an invasive-ductile carcinoma. Most common localizations of metastasis: bones (n = 19), lungs (n = 19), liver (n = 7). Tumor characteristics at the point of diagnosis: 63.9% (n = 22) T2-T4, 38.7% (n = 12) G3, 48.4% (n = 15) N+, 79.3% (n = 23) ER+, 72.4% (n = 21) PgR+, 12.5% (n = 3) HER-2+, 13.8% (n = 4) triple negatives, and 69.2% (n = 9) AR+. The therapy in the metastatic state was very heterogeneous and consisted of systemic endocrine therapy in 45.5% (n = 10), systemic chemo therapy in 9% (n = 2) or a combination of both in 45.5% (n = 10). In 14 (40%) cases a palliative radio therapy was administered. The initial tumor characteristics like tumor size, nodal state and grading were not of any prognostic relevance on a future development of metastasis. Prognostic unfortunate were a negative hormone receptor state (p < 0.001) and triple negative receptor state (n.s.). Patients with primary metastasis showed a tendency towards worse survival than patients who developed the metastasis during follow up (n.s.). If a systemic therapy was given the prognosis was significantly improved (p < 0.005). Conclusions: Patients suffering from metastatic male breast cancer had a comparatively good prognosis and showed significant benefit from systemic therapy in this study. In patients with negative receptor state and without systemic therapy the prognosis was especially worsened. Our data suggest that an up-to-date adequate systemic therapy is capable of improving survival in men with metastatic breast cancer. No significant financial relationships to disclose.

5-alpha reductase inhibitors and risk of male breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16013-e16013
Author(s):  
Mahyar Etminan ◽  
James Brophy ◽  
Abraham Hartzema ◽  
Joseph Delaney ◽  
Steven Bird
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Index Date ◽  
Male Breast ◽  
Partial Mastectomy ◽  
Physician Visits ◽  
Reductase Inhibitors ◽  
Procedural Code ◽  
5 Alpha Reductase Inhibitors

e16013 Background: 5-alpha reductase inhibitors (5ARIs), finasteride and dutasteride, are one of the most popular classes of medications used by older men. The drugs are mainly used for the treatment of benign prostatic hyperplasia (BPH). There have been 50 cases of breast cancer potentially linked to both finasteride and dutasteride reported to the FDA. However, to date, no epidemiologic study has examined this potential link. Methods: We used the LifeLink database (IMS, USA) as the main source of data for this study. The database captures information on approximately 70 million US residents who are enrolled in a private healthcare plan. The database captures information on prescription drugs, hospitalizations, physician visits and demographics. Breast cancer cases were defined as those with a diagnosis (ICD-9-CM 175.X) on two days and either a procedural code (CPT-4) for a mastectomy or a lumpectomy/partial mastectomy with evidence of follow-up treatment (radiation/chemotherapy). The index date was deemed the first diagnostic or procedural code for breast cancer. This definition has been found to have a 93% positive predictive value for incident breast cancer. For each case, twenty controls were selected from the database using risk set sampling and matched on age within 5 years, date of diagnosis within six weeks and follow up time prior to the index date. We used logistic regression to compute adjusted rate ratios. The model was adjusted for the following covariates: age, calendar year, alcoholism, gynecomastia, Klinefelter’s disease, liver damage, obesity, oral estrogen, orchiectomy, and prior radiation. Results: There were 429 male breast cancer cases and matched them to 13,240 controls. 341 (79.5%) met our primary ascertainment, while 88 (20.5%) additional cases met our secondary criteria. We found no increased risk with male breast cancer and use of 1 year (RR=0.70, [95% CI0.34-1.45]) or 3 years of 5-ARIs therapy (RR=0.71, [95% CI:0.25-1.98]). Conclusions: We found no harmful association between sue of 5-ARIs and risk of male breast cancer. Future studies are needed to refute or confirm these findings.

An NCDB analysis of trends in male breast cancer from 2004-2009 and 2010-2014.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 544-544
Author(s):  
Esther Dubrovsky ◽  
Shira Schwartz ◽  
Jennifer Chun ◽  
Amber Guth ◽  
Deborah M. Axelrod ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormonal Therapy ◽  
Male Breast ◽  
Adjuvant Hormonal Therapy ◽  
Stage At Diagnosis ◽  
Female Patients ◽  
Treatment Type ◽  
To Receive

544 Background: To examine the trends in clinicopathologic features, treatment, and survival of male breast cancer (MBC), utilizing the National Cancer Data Base (NCDB). Methods: MBC patients entered in the NCDB from 2004-2009 were compared with those from 2010-2014 for demographics, stage at diagnosis, tumor characteristics, treatment type, and overall survival (OS). Male patients were also compared to female patients from the same time periods. Statistical analysis included Pearson’s chi-square test. Results: Of 2,047,868 breast cancer cases, a total of 19,409 (0.95%) men were available for analysis. The group of MBC patients from 2004 to 2009 included 9,790 men with a median age of 65. The group from 2010 to 2014 included 9,619 men with a median age of 66. In the later group there was a decreased rate of DCIS, increased rate of invasive ductal carcinoma, and increased rate of hormone positive tumors. Among the earlier and later MBC groups, 24% vs. 27% of patients underwent lumpectomy. Of these, 61% vs 68% received post-lumpectomy radiation, respectively. Patients in the later group (2010-2014) were more likely to receive adjuvant hormonal therapy (61% vs. 84%, p < 0.0001). MBC patients were older than female patients (65 vs. 61 years, p < 0.0001), had larger tumors (20mm vs. 16mm, p < 0.0001), slightly later stage at diagnosis, and more likely to undergo mastectomy (74 vs. 42%, p < 0.0001). MBC patients also had higher rates of hormone positive tumors, but lower rates of adjuvant hormonal therapy (55% vs. 58%, p < 0.0001). The OS for male vs. female patients in the 2004-2009 groups was 66% vs. 77% (median follow-up 73.9m vs 80.4m) respectively. Similarly, in the 2010-2014 groups, survival was 84% vs. 90% (median follow-up 33.85m vs 35.91m), respectively. Conclusions: Although men have higher rates of hormone positive tumors, they are less likely to receive adjuvant hormonal therapy. There was a significant trend over time towards more standard therapies in men, such as post-lumpectomy radiation and hormonal therapy use. There has been an improvement of OS in men which mirrors that in women. The disparities in outcomes between male and female patients, however, still require further investigation.

scholarly journals Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Patients—A Mixed Methods Analysis

2018 ◽  
Vol 12 (6) ◽  
pp. 2194-2207 ◽  
Author(s):  
Evamarie Midding ◽  
Sarah Maria Halbach ◽  
Christoph Kowalski ◽  
Rainer Weber ◽  
Rachel Würstlein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mixed Methods ◽  
Male Breast Cancer ◽  
Qualitative Interviews ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Mixed Methods Design ◽  
Work Related ◽  
Care Systems

Male breast cancer (MBC) is rare and known as a typical woman’s disease. This study is part of the N-MALE project (Male breast cancer: patient’s needs in prevention, diagnosis, treatment, rehabilitation and follow-up-care) and aims to investigate how MBC patients (MBCP) feel about suffering from a “woman’s disease,” what character the stigmatization has, and how it can be prospectively reduced. Therefore, a mixed methods design is applied including data of N = 27 qualitative interviews with MBCP and quantitative data of N = 100 MBCP. Findings identify a diverse picture, as stigmatization varies between contexts and patients: Most stigmatization concentrates on sexual stigmatization and ignorance of MBC and mostly occurs in cancer care systems and work-related contexts. The level of stigmatization varies with age and amount of treatment methods received, as reported within the created typology of different MBCP stigma types. To prospectively reduce stigmatization in MBCP, more publicity of MBC is needed, as well as gender-neutral communication and information material.

Male Breast Cancer: Management and Follow-up Recommendations

2011 ◽  
Vol 17 (5) ◽  
pp. 503-509 ◽  
Author(s):  
John V. Kiluk ◽  
Marie Catherine Lee ◽  
Catherine K. Park ◽  
Tammi Meade ◽  
Susan Minton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Cancer Management ◽  
Breast Cancer Management

scholarly journals Survival Outcomes in Male Breast Cancer – A Single Institution Experience

2018 ◽  
Vol 3 (4) ◽  
pp. 71
Author(s):  
Nisha Hariharan
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Treatment Guidelines ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Survival Outcomes ◽  
Breast Cancers ◽  
Breast Cancer Patients

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.  

scholarly journals Male breast cancer a rare entity: the experience from North-East India

2019 ◽  
Vol 7 (1) ◽  
pp. 133
Author(s):  
Gaurav Das ◽  
Jitin Yadav ◽  
Joydeep Purkayastha ◽  
Abhijit Talukdar ◽  
Sachin Khanna
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Disease Free Survival ◽  
Male Breast ◽  
Free Survival ◽  
North East India ◽  
North East ◽  
Common Location ◽  
Common Malignancy

Background: Breast cancer is one of the most common malignancy among women but it is not common in men. Male breast cancer (MBC) is a rare disease and accounts for ∼1% of all cancers in men. There is lack of data related to MBC. The objective was to study the clinic-pathological characteristics and outcome of MBC patients at this institute.Methods: It is a retrospective study. Author analyzed clinico-pathological factors, management and follow up details of all patients with MBC from 2012 to 2018 at the cancer centre.Results: Total 20 patients were included in the study. No risk factor identified in any patient. The median age at diagnosis was 57.5 years. Most common location was central quadrant. Most common stage at presentation was stage 3. Fifteen patients underwent upfront surgery while neoadjuvant chemotherapy was given to two patients. One patient had complete pathological response (cPR). The median follow up was 24 months (4-60 months). Three patients developed local recurrence (3 chest wall and 1 axilla). Two patients developed distant metastasis (lung, liver and bone). Actual overall survival rate at 5 years was 67.5% with median disease-free survival was 55%.Conclusions: Multicentric trials are necessary to understand the predictive and prognostic markers and to improve the outcome in male breast cancer.

ATM germline variants and male breast cancer

2021 ◽  
Vol 14 (1) ◽  
pp. e238100
Author(s):  
Renato Cunha ◽  
Priscila Nejo ◽  
Sandra Bento ◽  
Fátima Vaz
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Germline Variants ◽  
Pathogenic Variants ◽  
Brca 1 ◽  
Brca 2 ◽  
Increase Risk

Male breast cancer is rare and has been frequently associated with cancer predisposing variants, particularly in BRCA 1 and BRCA 2 genes. ATM pathogenic variants may also increase risk for breast and other cancers. However, less than 10 cases relating ATM mutations and male breast cancer have been previously reported. Therefore, risk estimates and surveillance recommendations are not well established. We report a case of a male patient with breast cancer found to be heterozygous for a pathogenic ATM variant after multigene testing. We also review the literature regarding increased cancer risk associated with ATM germline variants, with emphasis on potential recommendations for surveillance and follow-up.

Male breast cancer: follow-up recommendations after surgery.

2009 ◽  
Author(s):  
C Laronga ◽  
MC Lee ◽  
CK Park ◽  
J Kiluk ◽  
T Meade ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Male Breast
Sign in / Sign up

Export Citation Format

Share Document